ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $227,813 | $211,371 | $197,122 | $190,574 |
| % Growth | 7.8% | 7.2% | 3.4% | – |
| Cost of Goods Sold | $116,021 | $74,615 | $73,037 | $80,280 |
| Gross Profit | $111,792 | $136,756 | $124,085 | $110,294 |
| % Margin | 49.1% | 64.7% | 62.9% | 57.9% |
| R&D Expenses | $12,304 | $16,535 | $10,564 | $16,646 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $76,656 | $81,771 | $76,528 | $69,719 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $24,558 | $10,799 | $28,307 |
| Operating Expenses | $88,960 | $122,864 | $97,891 | $114,672 |
| Operating Income | $22,832 | $13,892 | $26,194 | -$4,378 |
| % Margin | 10% | 6.6% | 13.3% | -2.3% |
| Other Income/Exp. Net | $10,968 | -$3,367 | -$6,207 | -$9,384 |
| Pre-Tax Income | $33,800 | $10,525 | $19,987 | -$13,762 |
| Tax Expense | $7,183 | $1,976 | $4,306 | -$3,486 |
| Net Income | $24,134 | $8,549 | $15,681 | -$10,276 |
| % Margin | 10.6% | 4% | 8% | -5.4% |
| EPS | 1.19 | 0.37 | 0.7 | -0.55 |
| % Growth | 221.6% | -47.1% | 227.3% | – |
| EPS Diluted | 1.13 | 0.36 | 0.69 | -0.55 |
| Weighted Avg Shares Out | 20,074 | 19,834 | 19,607 | 19,445 |
| Weighted Avg Shares Out Dil | 21,093 | 20,308 | 20,046 | 19,445 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2,784 | $2,623 | $0 |
| Interest Expense | $4,727 | $8,222 | $8,107 | $6,015 |
| Depreciation & Amortization | $22,632 | $23,281 | $22,891 | $22,600 |
| EBITDA | $61,159 | $39,244 | $48,362 | $14,853 |
| % Margin | 26.8% | 18.6% | 24.5% | 7.8% |